This study is testing whether an investigational drug called NX210c can slow the progression of ALS (amyotrophic lateral sclerosis). It will involve about 80 adults with ALS who will receive either the drug or a placebo through intravenous infusions. The main goals are to see if …
Phase: PHASE2 • Sponsor: Axoltis Pharma • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC